Science

[National Institutes of Health 2021 Grant]; psilcoybin in the treatment of tobacco use disorder…

“The funding side of the government has been the last to the party for a long time,” says Matthew Johnson, who studies psychedelics at Johns Hopkins University.

Grant Project Number 1U01DA052174-01A1: We hypothesize that psilocybin (compared to niacin) will cause increased biologically-confirmed 7-day point-prevalence abstinence at 12-month follow-up. Based on pilot data, we will test cognitive/psychological mediators of treatment response. We hypothesize that psilocybin will be associated with improved cognitive control and decreased anticipation of withdrawal relief (from smoking) 1 day after the target quit date, which will be associated with greater 7-day point-prevalence abstinence at 12- month follow-up… [Johns Hopkins University in Maryland.]

Original Article (NIH Report and Axios):
5-HT2A agonist psilocybin in the treatment of tobacco use disorder & The science of psychedelic therapy breaks on through
Artwork Fair Use: MRaccine

Spirituality

LSD… benefits…

Psychology

…salvinorin…

Anthropology

There will be oil

Anthropology

Cannabis goes green

Psychology

Home grow…

Psychology

…for macrodosing

Politics

First, it was weed…

Politics

Manufacturing…

Spirituality

…the Mushroom

Politics

Oregon psilocybin…

Science

What is kratom…?

Politics

SITSA … stopped

Politics

Grassy Globes

Politics

Weed wages water war

Politics

Big acid

Politics

Can Kratom be patented?

Science

Kratom LD-50 Stats

Science

Rolling in the deep

Science

The Peace Drug